The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
PX-866 and docetaxel in patients with advanced solid tumors.
Antonio Jimeno
Research Funding - Oncothyreon
Neil N. Senzer
No relevant relationships to disclose
Charles M. Rudin
Consultant or Advisory Role - AVEO; Genentech; Novartis; Oncothyreon
Wen Wee Ma
No relevant relationships to disclose
Balazs Halmos
Research Funding - Daiichi Sankyo; Lilly; Oncothyreon; Pfizer
Ian D. Schnadig
No relevant relationships to disclose
Benjamin Levy
No relevant relationships to disclose
Diana Felice Hausman
Employment or Leadership Position - Oncothyreon
Stock Ownership - Oncothyreon
Scott Peterson
Employment or Leadership Position - Oncothyreon
Stock Ownership - Oncothyreon
Luke N. Walker
Employment or Leadership Position - Oncothyreon
Stock Ownership - Oncothyreon